Breast Cancer Clinical Trials in Annapolis, Maryland

7 studies are recruiting for breast cancer in Annapolis, Maryland right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

   The purpose of this study is to assess the safety of GDC-4198 alone and in combination with giredestrant and also the efficacy of GDC-4198 + giredestrant versus abemaciclib + giredestrant in participants with locally advanced or metastatic ER+, HER2- breast cancer. The study consists of 2 phases: P…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Maryland Oncology Hematology - Annapolis, Annapolis, Maryland

   Locations

   64 in total

   Run by

   Genentech, Inc.

   See if you can join NCT07100106 on ClinicalTrials.gov

2. A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

   This study will evaluate the efficacy and safety of the combination of inavolisib plus a cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) and letrozole versus placebo plus a CDK4/6i and letrozole in the first-line setting in participants with endocrine-sensitive PIK3CA-mutated hormone receptor-p…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Velocity Clinical Research, Annapolis, Maryland

   Locations

   241 in total

   Run by

   Hoffmann-La Roche

   See if you can join NCT06790693 on ClinicalTrials.gov

3. Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

   This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with es…

   Stage

   Phase 3

   Ages

   18 to 60

   Site

   Luminis Health Anne Arundel Medical Center, Annapolis, Maryland

   Locations

   1261 in total

   Run by

   NRG Oncology

   See if you can join NCT05879926 on ClinicalTrials.gov

4. Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

   This phase 3 clinical trial compares the efficacy and safety of palazestrant with ribociclib to letrozole and ribociclib in women and men who have not received prior systemic anti-cancer treatment for advanced breast cancer.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Clinical Trial Site, Annapolis, Maryland

   Locations

   181 in total

   Run by

   Olema Pharmaceuticals, Inc.

   See if you can join NCT07085767 on ClinicalTrials.gov

5. Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

   This is a prospective, randomized, double-blinded, placebo-controlled, multi-center, Phase 3 study of GLSI-100 immunotherapy in HLA-A*02 positive and HER2/neu positive subjects who are at high risk for disease recurrence and have completed both neoadjuvant and postoperative adjuvant standard of car…

   Stage

   Phase 3

   Ages

   18 to 100

   Site

   Maryland Oncology Hematology, Annapolis, Maryland

   Locations

   179 in total

   Run by

   Greenwich LifeSciences, Inc.

   See if you can join NCT05232916 on ClinicalTrials.gov

6. A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

   The purpose of this study is to learn about the safety and effects of the study medicine PF-07248144 when given along with fulvestrant for the possible treatment of HR-positive, HER2-negative advanced or metastatic breast cancer. HR-positive breast cancer cells have proteins on their surface called…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Maryland Oncology Hematology P.A., Annapolis, Maryland

   Locations

   202 in total

   Run by

   Pfizer

   See if you can join NCT07062965 on ClinicalTrials.gov

7. MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles

   The FLEX Registry will be implemented to operate as a large-scale, population based, prospective registry. All patients with stage I to III breast cancer who receive MammaPrint® and BluePrint testing on a primary breast tumor are eligible for entry into the FLEX Registry, which is intended to enabl…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Luminis Health Center for Cancer & Blood Disorders, Annapolis, Maryland

   Locations

   134 in total

   Run by

   Agendia

   See if you can join NCT03053193 on ClinicalTrials.gov